#USA #San Diego #Cancer Treatment #Monoclonal Antibodies #Precision Biologics

Presentation at the Festival of Biologics USA

Precision Biologics, Inc. is set to make waves in the medical community as it presents its recent advancements in monoclonal antibodies targeting tumor-specific neoepitopes at the upcoming Festival of Biologics USA, scheduled for March 4-5, 2026, at the San Diego Convention Center in California. The discussion will be led by CEO Dr. Philip M. Arlen, who has been at the forefront of this innovative research.

Focus of the Presentation

The presentation, titled "Discovery and Development of Monoclonal Antibodies Targeting Tumor Specific Neoepitopes," will take place on the second day of the festival at 12:20 PM. Dr. Arlen's talk will delve into the unique attributes of their monoclonal antibodies (mAb), designed specifically to target proteins prevalent on a myriad of human solid tumors without affecting most healthy tissues. This precision in targeting is a game-changer in cancer therapy, providing a pathway to treatments that are effective while minimizing unwanted side effects.

Dr. Arlen explains, "Most anticancer drugs find it challenging to differentiate between cancerous and healthy cells, as they often target proteins that exist on both. Our monoclonal antibodies aim for a more selective approach, resulting in therapies that are not just powerful but specifically tailored for cancer cells."

The Domestic Landscape of Cancer Treatment

With growing concerns surrounding the side effects of traditional chemotherapies, Precision Biologics is keen to highlight the importance of developing therapeutics that focus solely on malignant cells. By enhancing the understanding of these cancer-specific targets, the company hopes to foster advancements in treatment efficacy.

This initiative is particularly crucial as cancer remains one of the leading causes of mortality worldwide, making the need for focused therapies more pressing than ever. The research presented by Precision Biologics is poised to inspire further innovations in the field of oncology, meeting the urgent demand for safer and more effective cancer treatments.

About the Festival of Biologics USA

The Festival of Biologics is widely recognized as a premier gathering for the biotechnology industry, bringing together leaders, innovators, and researchers from around the globe. It serves as a platform to exchange ideas, share discoveries, and enhance collaboration within the sector. Precision Biologics' participation exemplifies the ongoing commitment to advancing cancer research and therapeutic options.

With growing intense interest in monoclonal antibody therapies, Dr. Arlen's presentation symbolizes a significant milestone for Precision Biologics and the broader scientific community. As cancer research continues to evolve, the insights shared at this festival are expected to have a lasting impact on the future of cancer care.

Dr. Arlen is known for his thought leadership in the field, and this presentation is part of a larger strategy to expand clinical and scientific awareness of the promising capabilities that monoclonal antibodies hold in treating cancer. Look out for updates from the event as the medical community gathers to discuss the latest breakthroughs.

For those attending, visiting the Precision Biologics booth will also offer a chance to meet the team behind these innovations and engage in discussions about future developments in cancer treatment.

Event Details:

• - Title: Discovery and Development of Monoclonal Antibodies Targeting Tumor Specific Neoepitopes
• - Date: March 5, 2026
• - Time: 12:20 PM
• - Location: San Diego Convention Center, San Diego, CA
• - Speaker: Philip M. Arlen, M.D., President and CEO, Precision Biologics, Inc.

With this presentation, Precision Biologics aims not only to enhance awareness but also to pave the way for novel therapeutic strategies in the incessant fight against cancer.